Gabather AB (GABA) AI Stock Analysis

Gabather AB

(Nasdaq OMX AB:GABA)

Select Model

Rating:37Underperform

Price Target:SEK 0.02▼(-5.00% Downside)

Action:reiterated

Date:10/31/26

The overall score is at the minimum of 37, reflecting extreme risk across all evaluated components. The company is pre-revenue with ongoing cash burn, a shrinking asset base, and a complete dependence on external financing. Technical indicators confirm a persistent downtrend with deeply oversold conditions and no signs of reversal. The negative P/E ratio and lack of dividends provide no valuation support. This is a high-risk, early-stage pharmaceutical company with significant fundamental and market headwinds.

Positive Factors

Debt-Free Balance SheetThe absence of reported debt reduces fixed financial obligations and interest expense, giving Gabather greater flexibility while it advances its drug candidates. This can help preserve strategic options and limit balance-sheet pressure during the company’s ongoing pre-revenue development phase.

Negative Factors

No Revenue or Commercial BaseZero revenue means Gabather has not yet demonstrated commercial demand or established a recurring inflow to support operations. Until a candidate reaches commercialization or another source of operating income emerges, business value remains dependent on successful development milestones and external funding.

Gabather AB (GABA) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 12.21M
Dividend Yield: ―
Average Volume (3M): 2.63M
Price to Earnings (P/E): -1.2
Beta (1Y): 0.86
Revenue Growth: ―
EPS Growth: 65.27%
Country: Sweden
Employees: 2
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Gabather AB Business Overview & Revenue Model

Company Description

Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorder...

Gabather AB Financial Statement Overview

Summary

The company is pre-revenue with persistent operating losses, resulting in the lowest possible income statement score. While the balance sheet has zero debt and a slightly positive equity position, the asset base is shrinking and cash flow remains deeply negative, creating significant going-concern risk. The overall financial health is precarious, typical of a high-risk clinical-stage pharmaceutical company.

Income Statement

1Very Negative

Balance Sheet

25Negative

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0
EBITDA	-4.90M	-4.53M	0	37.00K	3,000	-16.91M
Net Income	-5.00M	-4.65M	-7.75M	-9.44M	-8.54M	-17.00M
Balance Sheet
Total Assets	4.54M	3.83M	1.83M	7.36M	6.75M	15.39M
Cash, Cash Equivalents and Short-Term Investments	3.69M	3.14M	878.00K	1.11M	6.27M	14.85M
Total Debt	0	0	0	0	0	0
Total Liabilities	3.08M	4.69M	6.01M	6.88M	3.31M	4.43M
Stockholders Equity	1.46M	-863.00K	-4.17M	486.00K	3.44M	10.96M
Cash Flow
Free Cash Flow	-7.13M	-7.22M	-3.33M	-11.64M	-9.60M	-16.12M
Operating Cash Flow	-7.13M	-7.22M	-3.33M	-11.64M	-9.60M	-16.12M
Investing Cash Flow	0	0	0	0	0	0
Financing Cash Flow	7.82M	9.49M	3.09M	6.49M	1.02M	46.00K

Gabather AB Technical Analysis

Technical Analysis SentimentNegative

Last Price0.02

Price Trends

50DMA0.03Negative

100DMA0.03Negative

200DMA0.03Negative

Market Momentum

MACD-0.00Positive

RSI39.04Neutral

STOCH12.50Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GABA, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 39.04 is Neutral, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GABA.

Gabather AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:GABA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CAMX	80Outperform	SEK 40.76B	59.09	15.54%	―	<0.01%	-6.75%
SE:SANION	77Outperform	SEK 1.54B	8.30	29.71%	―	24.98%	-31.44%
SE:BIOA.B	65Neutral	SEK 28.15B	266.55	5.18%	0.68%	-46.09%	-90.13%
SE:ALZCUR	55Neutral	SEK 882.54M	42.87	65.99%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:GABA	37Underperform	SEK 12.21M	-1.20	-2479.40%	―	―	65.27%
SE:ORX	32Underperform	SEK 163.96M	-0.44	-115.03%	―	-97.68%	-83.26%

* Healthcare Sector Average

Performance Comparison

SE:GABA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:GABA	Gabather AB	0.02	-0.02	-50.00%
SE:CAMX	Camurus AB	674.00	63.00	10.31%
SE:ORX	Orexo AB	4.21	-22.80	-84.43%
SE:ALZCUR	AlzeCure Pharma AB	6.36	4.50	241.02%
SE:BIOA.B	BioArctic AB Class B	310.20	27.68	9.80%
SE:SANION	Saniona AB	10.55	-5.75	-35.28%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

Gabather AB AI Stock Analysis